FDA broadens label for Amgen's Uplizna as it enters rare disease competition
FDA broadens label for Amgen's Uplizna as it enters rare disease competition
Contenu indisponible. Consultez la source originale.
FDA broadens label for Amgen's Uplizna as it enters rare disease competition